drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-T)
drug_description
An autologous CD19-directed CAR-T cell therapy generated by retroviral transduction; the CAR contains CD3ζ and costimulatory domains that enhance cytokine-driven JAK/STAT signaling to promote T-cell activation, proliferation, and cytotoxic killing of CD19-positive malignant B cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are retrovirally transduced to express a CD19-specific chimeric antigen receptor containing CD3ζ and costimulatory domains. Engagement of CD19 on malignant B cells triggers CAR-mediated signaling (including cytokine-driven JAK/STAT pathways), leading to T-cell activation, proliferation, and targeted cytotoxic killing of CD19-positive cells.
drug_name
TBI-2001
nct_id_drug_ref
NCT05963217